Diagnosed cases of sepsis exceed 18 million a year with 1,400 patients dying daily in the developed world. Rapid treatment is critical to a patient’s recovery and therefore the time taken to diagnose sepsis is key.
This new technique is not dependent upon needing the symptoms of sepsis to be clinically displayed. Instead, a set of biomarkers are used in suspected patients to diagnose the presence of sepsis before the symptoms appear.
This allows the identification of sepsis in a patient much earlier, extending the treatment window and making it more effective.
Benefits
| i | Therapeutic window extended and mortality rates reduced |
| i | Cost of treatment lowered |
| i | Can discriminate between sepsis, SIRS, and negative controls |
| i | Compatible with RT-qPCR formats for rapid results |
Also see
Properties
Project number
P1628
Patent status
GB grant (2527164)
EP application (15701566.0)
Commercial rights
Sole Rights / Non-exclusive
Source
Dstl
Regions
Worldwide
Available to license
Yes
Sectors
Download datasheet
For more details, including discrimination rates between sepsis and SIRS, please enter your email address below to access the datasheet.
For more information about licensing this technology, or to speak to us about our other defence and security related intellectual property, please contact us.